PRESS RELEASE published on 02/28/2025 at 07:30, 1 year ago Informations privilégiées / Autres communiqués ABIONYX s’engage dans la Déficience LCAT (Maladie de Norum) en soutenant les patients et préparant l'AMM, bénéficiant de la Désignation de Maladie Orpheline en Europe et aux USA ABIONYX EMA Déficience LCAT Maladie De Norum Désignation Orpheline
PRESS RELEASE published on 02/28/2025 at 07:30, 1 year ago Inside Information / Other news releases ABIONYX renews commitment to treat LCAT Deficiency (Norum's disease) and provides updates on advances, including submission of Marketing Authorization Application and Orphan Disease Designation ABIONYX LCAT Deficiency Rare Disease Day Marketing Authorization Application Orphan Disease Designation
BRIEF published on 02/27/2025 at 19:25, 1 year ago ABIONYX Pharma Reports Stable Revenue and Cash Position for 2024 2024 Financial Results Innovative Therapies ABIONYX Pharma Compassionate Access CRO Industry
BRIEF published on 02/27/2025 at 19:25, 1 year ago ABIONYX Pharma annonce un chiffre d'affaires et une situation de trésorerie stables pour 2024 Résultats Financiers 2024 ABIONYX Pharma Thérapies Innovantes Accès Compassionnel Industrie Des CRO
PRESS RELEASE published on 02/27/2025 at 19:20, 1 year ago Inside Information / Information on annual revenues ABIONYX Pharma reports €4.6m revenue and €3.2m cash at the end of Q4 2024. Details on business activities and financial performance included Revenue Cash Position Financial Update Biopharma ABIONYX Pharma
PRESS RELEASE published on 02/27/2025 at 19:20, 1 year ago Informations privilégiées / Information sur chiffre d’affaires annuel ABIONYX Pharma annonce un chiffre d'affaires consolidé de 4,6M€ et une trésorerie de 3,2M€ au 31 décembre 2024 Chiffre D'affaires Trésorerie Biopharma ABIONYX Pharma Thérapies Innovantes
BRIEF published on 02/20/2025 at 07:35, 1 year 1 month ago ABIONYX Pharma reçoit un soutien de 8,7 millions d'euros pour son projet sur le sepsis France 2030 ABIONYX Pharma Sepsis Soutien Financier Biomédicament
BRIEF published on 02/20/2025 at 07:35, 1 year 1 month ago ABIONYX Pharma receives €8.7 million in support for its sepsis project Financial Support France 2030 ABIONYX Pharma Sepsis Biomedicine
PRESS RELEASE published on 02/20/2025 at 07:30, 1 year 1 month ago Informations privilégiées / Autres communiqués ABIONYX Pharma reçoit 8,7 M€ de soutien de l’Etat pour combattre le sepsis, 3ème cause de décès mondiale, grâce à son biomédicament CER-001 France 2030 ABIONYX Pharma Sepsis Soutien Financier Biomédicament
BRIEF published on 12/11/2024 at 12:16, 1 year 3 months ago Franchissement de seuil par la CDC dans ABIONYX PHARMA Droits De Vote Franchissement De Seuil CDC ABIONYX Pharma Bpifrance Participations
Published on 03/24/2026 at 13:30, 1 hour 23 minutes ago GGL Resources Corp. Announces Closing of Earn-In Agreement with Nelson Resources Limited on Its Gold Point High-Grade Gold-Silver Project, Nevada
Published on 03/24/2026 at 13:30, 1 hour 23 minutes ago Innodata Announces Date of Annual Shareholder Meeting
Published on 03/24/2026 at 12:35, 2 hours 18 minutes ago Silver X Acquires the High-Grade Pampas Gold-Silver Project, Expanding its Precious Metal Asset Base in Peru
Published on 03/24/2026 at 12:33, 2 hours 20 minutes ago Mako Mining Completes Acquisition of Mt. Hamilton in Nevada
Published on 03/24/2026 at 12:30, 2 hours 23 minutes ago Orogen Reports Record 2025 Financial Performance and Positions for Continued Growth in 2026
Published on 03/24/2026 at 14:45, 7 minutes ago CoinShares Digital Securities Limited: EU CSDSL Index - Additional Custodian (24/03/2026)
Published on 03/24/2026 at 14:39, 13 minutes ago Original-Research: Jaguar Health Inc (von First Berlin Equity Research GmbH): BUY
Published on 03/24/2026 at 14:30, 22 minutes ago EQS-Adhoc: Sibanye Gold Limited: USD 500,000,000 4.250 per cent. Guaranteed Unsecured Convertible Bonds due 2028
Published on 03/24/2026 at 14:27, 25 minutes ago Form 8.3 - The Vanguard Group, Inc.: Bluefield Solar Income Fund Limited
Published on 03/24/2026 at 10:58, 3 hours 55 minutes ago Statement about the number of shares composing the share capital and the number of voting rights as of February 28, 2026
Published on 03/24/2026 at 10:58, 3 hours 55 minutes ago Déclaration du nombre d'actions composant le capital social et du nombre total de droits de vote au 28 février 2026
Published on 03/24/2026 at 07:45, 7 hours 8 minutes ago François Jackow’s appointment as a Board member will be submitted to the Annual General Meeting on May 7, 2026
Published on 03/24/2026 at 07:45, 7 hours 8 minutes ago La nomination de François Jackow en tant que membre du Conseil d’administration sera soumise à l’Assemblée générale du 7 mai 2026
Published on 03/24/2026 at 07:30, 7 hours 23 minutes ago Gimv secures new EUR 400 million revolving credit facility to support accelerated growth ambitions
